Nakamoto et al., 2000 - Google Patents
Delayed 18F‐fluoro‐2‐deoxy‐D‐glucose positron emission tomography scan for differentiation between malignant and benign lesions in the pancreasNakamoto et al., 2000
View PDF- Document ID
- 11973643057266550329
- Author
- Nakamoto Y
- Higashi T
- Sakahara H
- Tamaki N
- Kogire M
- Doi R
- Hosotani R
- Imamura M
- Konishi J
- Publication year
- Publication venue
- Cancer
External Links
Snippet
BACKGROUND Positron emission tomography (PET) using 18F‐fluoro‐2‐deoxy‐D‐glucose (FDG) has been used for the evaluation of various tumors, but accumulation in inflammatory lesions makes it a controversial modality. The aim of this study was to investigate the …
- 238000002600 positron emission tomography 0 title abstract description 93
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/574—Immunoassay; Biospecific binding assay for cancer
- G01N33/57407—Specifically defined cancers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Hybridisation probes
- C12Q1/6883—Hybridisation probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/04—X-ray contrast preparations
- A61K49/0409—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is not a halogenated organic compound
- A61K49/0414—Particles, beads, capsules or spheres
- A61K49/0423—Nanoparticles, nanobeads, nanospheres, nanocapsules, i.e. having a size or diameter smaller than 1 micrometer
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Nakamoto et al. | Delayed 18F‐fluoro‐2‐deoxy‐D‐glucose positron emission tomography scan for differentiation between malignant and benign lesions in the pancreas | |
Delbeke et al. | Optimal interpretation of FDG PET in the diagnosis, staging and management of pancreatic carcinoma | |
Eubank et al. | Impact of FDG PET on defining the extent of disease and on the treatment of patients with recurrent or metastatic breast cancer | |
Rusthoven et al. | The role of fluorodeoxyglucose positron emission tomography in cervical lymph node metastases from an unknown primary tumor | |
Fuster et al. | Preoperative staging of large primary breast cancer with [18F] fluorodeoxyglucose positron emission tomography/computed tomography compared with conventional imaging procedures | |
Arnaud et al. | Is 18F‐fluorodeoxyglucose positron emission tomography scanning a reliable way to assess disease activity in Takayasu arteritis? | |
Welin et al. | Elevated plasma chromogranin A is the first indication of recurrence in radically operated midgut carcinoid tumors | |
Tan et al. | Comparison of MRI, F-18 FDG, and 11C-choline PET/CT for their potentials in differentiating brain tumor recurrence from brain tumor necrosis following radiotherapy | |
Israel et al. | Is 18F-FDG PET/CT useful for imaging and management of patients with suspected occult recurrence of cancer? | |
Fueger et al. | Comparison of CT, PET, and PET/CT for staging of patients with indolent non-Hodgkin’s lymphoma | |
Pfluger et al. | PET/CT in malignant melanoma: contrast-enhanced CT versus plain low-dose CT | |
Murakami et al. | FDG-PET/CT in the diagnosis of recurrent breast cancer | |
Marner et al. | Early postoperative 18F-FET PET/MRI for pediatric brain and spinal cord tumors | |
Ristau et al. | Impact of primary staging with fibroblast activation protein specific enzyme inhibitor (FAPI)-PET/CT on radio-oncologic treatment planning of patients with esophageal cancer | |
Filippi et al. | Recent advances in PET probes for hepatocellular carcinoma characterization | |
Izuishi et al. | Impact of 18-fluorodeoxyglucose positron emission tomography on the management of pancreatic cancer | |
Querellou et al. | Prognostic value of fluorine‐18 fluorodeoxyglucose positron‐emission tomography imaging in patients with head and neck squamous cell carcinoma | |
Iagaru et al. | Detection of occult medullary thyroid cancer recurrence with 2-deoxy-2-[F-18] fluoro-D-glucose-PET and PET/CT | |
Zhao et al. | 18F-fluorodeoxyglucose positron emission tomography/computed tomography as an effective diagnostic workup in cervical metastasis of carcinoma from an unknown primary tumor | |
Liu et al. | One-stop [18F] FDG and [68Ga] Ga-DOTA-FAPI-04 total-body PET/CT examination with dual-low activity: a feasibility study | |
Watanabe et al. | The usefulness of 18 F-FDG PET/CT for assessing methotrexate-associated lymphoproliferative disorder (MTX-LPD) | |
Sohn et al. | Is there an additive value of 18 F-FDG PET-CT to CT/MRI for detecting nodal metastasis in oropharyngeal squamous cell carcinoma patients with palpably negative neck? | |
Baiocchi et al. | Possible additional value of 18FDG-PET in managing pancreas intraductal papillary mucinous neoplasms: preliminary results | |
Pu et al. | The clinical application of 18F-FDG PET/CT in pancreatic cancer: a narrative review | |
Amorim et al. | Performance of 18 F-fluciclovine PET/MR in the evaluation of osseous metastases from castration-resistant prostate cancer |